Gastrointestinal Stromal Tumor (GIST) Market is driven by Precision Medicine
The gastrointestinal stromal tumor (GIST) market encompasses innovative targeted therapies, including tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. These products offer significant advantages over traditional chemotherapy by blocking specific oncogenic pathways, reducing off-target toxicity, and improving patient outcomes....
0 Commentaires 0 Parts 98 Vue 0 Aperçu